Medtronic (MDT) Projected to Post Quarterly Earnings on Wednesday

Medtronic (NYSE:MDT) is projected to announce its Q4 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of $1.58 per share and revenue of $8.81 billion for the quarter. Medtronic has set its FY 2025 guidance at 5.440-5.500 EPS.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.36 by $0.03. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. The firm had revenue of $8.29 billion during the quarter, compared to analyst estimates of $8.33 billion. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Trading Up 0.4%

Shares of Medtronic stock opened at $86.41 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.39 and a debt-to-equity ratio of 0.48. Medtronic has a 12-month low of $75.96 and a 12-month high of $96.25. The firm has a market capitalization of $110.83 billion, a price-to-earnings ratio of 26.27, a PEG ratio of 2.22 and a beta of 0.81. The firm’s 50 day simple moving average is $85.93 and its two-hundred day simple moving average is $86.60.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 11th. Shareholders of record on Friday, March 28th were paid a dividend of $0.70 per share. The ex-dividend date of this dividend was Friday, March 28th. This represents a $2.80 dividend on an annualized basis and a yield of 3.24%. Medtronic’s payout ratio is 85.11%.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $105.00 price target on shares of Medtronic in a research note on Wednesday, February 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a report on Wednesday, February 19th. Citigroup raised shares of Medtronic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $92.00 to $107.00 in a report on Tuesday, March 4th. Robert W. Baird upped their price objective on shares of Medtronic from $90.00 to $91.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. Finally, Truist Financial lowered their price target on shares of Medtronic from $93.00 to $90.00 and set a “hold” rating on the stock in a report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Hold” and a consensus target price of $96.14.

Institutional Investors Weigh In On Medtronic

A hedge fund recently raised its stake in Medtronic stock. Brighton Jones LLC grew its holdings in Medtronic plc (NYSE:MDT) by 1,368.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,989 shares of the medical technology company’s stock after buying an additional 37,265 shares during the period. Brighton Jones LLC’s holdings in Medtronic were worth $3,194,000 as of its most recent filing with the Securities & Exchange Commission. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.